{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T07:19:23Z","timestamp":1782371963049,"version":"3.54.5"},"reference-count":29,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2009,6,22]],"date-time":"2009-06-22T00:00:00Z","timestamp":1245628800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2009,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>Cholinesterase Inhibitors (CEIs) have been subsidised in Australia since February 2001 for cognitive decline associated with mild to moderate Alzheimer disease. The number of people with Alzheimer Disease is expected to increase, with a continuing increase in the number of people receiving CEI's. Many anticholinergic drugs (ACDs) are also prescribed to people receiving CEIs and concerns about the impact of the interaction have been raised. The aim of this study was to describe co\u2010prescribing of a group of important ACDs in patients initiating treatment with CEIs in Australia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Pharmacy claim data for Australia (Pharmaceutical Benefits Scheme) was examined for the period 1 April to 30 June 2006. All selected prescriptions supplied for patients receiving their first supply of any CEIs (initiators) were extracted for 14 weeks prior to and post the first date of supply. The numbers of initiating people co\u2010administering CEIs and ACDs was examined.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>5797 persons received their first prescription for CEIs between 1 April and 30 June 2006. Thirty\u2010two per cent of these also received prescriptions for at least one ACD. There was a statistically significant increase in the number of initiators receiving an ACD. The significant increase was in patients receiving atypical antipsychotics. There was a trend towards an increase in patients receiving oxybutynin.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Extent of co\u2010administration of ACDs and CEIs is similar to other international studies however the most significant increase is seen in patients receiving atypical antipsychotics. The implications of adding atypical antipsychotics are potential for worsening disease, increasing adverse effects and increased health resource utilisation in this vulnerable group. Copyright \u00a9 2009 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.1739","type":"journal-article","created":{"date-parts":[[2009,7,1]],"date-time":"2009-07-01T01:51:25Z","timestamp":1246413085000},"page":"659-664","source":"Crossref","is-referenced-by-count":24,"title":["Changes in utilisation of anticholinergic drugs after initiation of cholinesterase inhibitors"],"prefix":"10.1002","volume":"18","author":[{"given":"M","family":"Robinson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Rowett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Leverton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Mabbott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,6,22]]},"reference":[{"key":"e_1_2_1_2_2","unstructured":"Australian Institute of Health and Welfare (AIHW)2006;Dementia in Australia:national data analysis and development AIHW Cat no. AGE 53 Canberra:AIHW."},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005593"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra040223"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1989.00390110020006"},{"key":"e_1_2_1_6_2","first-page":"153","article-title":"Anticholineric effects of common pharmacological treatments in the elderly","volume":"2","author":"Mintzer J","year":"2000","journal-title":"J Geriatr Psychopharm"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2004.52563.x"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2006.104034"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.161.8.1099"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.38740.439664.DE"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100035"},{"key":"e_1_2_1_12_2","first-page":"83422","article-title":"Physical and cognitive performance and burden of anticholinergics, sedatives and ACE inhibitors in older women","author":"Cao YJ","year":"2008","journal-title":"Clin Pharmacol and Therapeutics"},{"issue":"5","key":"e_1_2_1_13_2","first-page":"23","article-title":"Psychopharmacology in the elderly person with cardiovascular disease","volume":"14","author":"Leigh\u2010Pemberton RA","year":"2006","journal-title":"Ann Long Term Care: Clinical Care and Ageing"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2007.07.006"},{"key":"e_1_2_1_15_2","unstructured":"Access Economics.Dementia estimates and projections: Australian states and territories. Report by Access Economics Pty Limited for Alzheimer's Australia. February 2005 (available athttp:\/\/www. accesseconomics.com.au\/publicationsreports)."},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67889-0"},{"key":"e_1_2_1_17_2","first-page":"65","article-title":"Demenia and Alzheimer's disease","volume":"88","author":"Roller L","year":"2007","journal-title":"Aust J Pharm"},{"key":"e_1_2_1_18_2","unstructured":"Australian Government.Australian Statistics on Medicines2007; Canberra."},{"issue":"5","key":"e_1_2_1_19_2","first-page":"275","article-title":"Use of specific drugs for Alzheimer's disease","volume":"22","author":"Villar Fernandez","year":"2007","journal-title":"Neurologia"},{"key":"e_1_2_1_20_2","unstructured":"Drug Consumption in Norway 2003\u20102007 available athttp:\/\/www.drugconsumption.noaccessed November2008."},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270006292126"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2007.106"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.165.7.808"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200825100-00006"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1600"},{"key":"e_1_2_1_26_2","unstructured":"Anon.Atypical antipsychotics and the geriatric patient: balancing safety and efficacy. Geriatrics (suppl) July2007."},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra052321"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2005.53487_9.x"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2202-9-86"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0806994"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.1739","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.1739","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.1739","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T11:46:37Z","timestamp":1699962397000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.1739"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6,22]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["10.1002\/pds.1739"],"URL":"https:\/\/doi.org\/10.1002\/pds.1739","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,6,22]]}}}